CARNA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 408 JPY | -3.32% |
|
-10.72% | -21.84% |
| Sales 2022 | 1.39B 9.09M 759M | Sales 2023 | 1.62B 10.66M 890M | Capitalization | 8.95B 58.71M 4.9B |
|---|---|---|---|---|---|
| Net income 2022 | -1.35B -8.85M -739M | Net income 2023 | -1.15B -7.56M -631M | EV / Sales 2022 | 3.11 x |
| Net cash position 2022 | 3.08B 20.2M 1.69B | Net cash position 2023 | 2.71B 17.76M 1.48B | EV / Sales 2023 | 3.84 x |
| P/E ratio 2022 |
-5.25
x | P/E ratio 2023 |
-7.61
x | Employees | 67 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.76% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.32% | ||
| 1 week | -10.72% | ||
| Current month | -14.82% | ||
| 1 month | -16.56% | ||
| 3 months | -12.26% | ||
| 6 months | -39.73% | ||
| Current year | -21.84% |
1 week
407.00
463.00
1 month
407.00510.00
Current year
407.00543.00
1 year
407.001 060.00
3 years
407.001 736.00
5 years
407.003 300.00
10 years
407.006 030.00
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 75 | 10/03/10 | |
Emi Yamamoto
ADM | Chief Administrative Officer | 53 | 01/04/01 |
Masaaki Sawa
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/07/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Teruo Takayanagi
BRD | Director/Board Member | 77 | 01/15/01 |
Tsuguo Ogasawara
BRD | Director/Board Member | 84 | 01/05/01 |
| President | 75 | 10/03/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 408 | -3.32% | 228,900 |
| 01/24/01 | 422 | -2.09% | 225,400 |
| 30/24/30 | 431 | +0.70% | 60,700 |
| 26/24/26 | 428 | -2.28% | 182,300 |
| 25/24/25 | 438 | -3.10% | 91,600 |
Delayed Quote Japan Exchange, May 02, 2024 at 11:30 am IST
More quotes
Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
Calendar
10/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -21.84% | 45.48M | |
| +24.94% | 48.09B | |
| +47.47% | 40.62B | |
| -2.99% | 40.43B | |
| -6.20% | 28.36B | |
| +7.40% | 24.89B | |
| -19.31% | 19.01B | |
| +29.45% | 12.09B | |
| -0.87% | 11.88B | |
| -1.26% | 11.8B |
- Stock Market
- Equities
- 4572 Stock
